A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome

Cancer

Volumn 118, Issue 3, 2012, Pages 722-728

  Faderl, Stefan ^a   Garcia Manero, Guillermo ^a   Jabbour, Elias ^a   Ravandi, Farhad ^a   Borthakur, Gautam ^a   Estrov, Zeev ^a   Gandhi, Varsha ^a   Byrd, Anna L ^a   Kwari, Monica ^a   Cortes, Jorge ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

clofarabine; DNA methyltransferase inhibitors; myelodysplastic syndrome; nucleoside analogs

Indexed keywords

CLOFARABINE; DNA METHYLTRANSFERASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ADULT; AGED; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; BONE PAIN; BRAIN HEMORRHAGE; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TREATMENT FAILURE; EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HIGH RISK PATIENT; HUMAN; HYPERBILIRUBINEMIA; INFECTION; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; SENSORY NEUROPATHY; SIDE EFFECT; TREATMENT RESPONSE; TREMOR; VOMITING; WEAKNESS;

ADENINE NUCLEOTIDES; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84856232797     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26327     Document Type: Article

References (19)

1. Catenacci DVT, Schiller GJ,. Myelodysplastic syndromes: a comprehensive review. Blood Rev. 2005; 19: 301-319.
2. Greenberg P, Cox C, LeBeau MM, et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 2079-2088.
3. Malcovati L, Della Porta MG, Cazzola M,. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica. 2006; 91: 1588-1590.
4. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355: 1456-1465.
5. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002; 20: 2429-2440.
6. Kantarjian H, Issa J-P, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer. 2006; 106: 1794-1803.
7. Kantarjian HM, Jeha S, Gandhi V, et al. Clofarabine: past, present, and future. Leuk Lymphoma. 2007; 48: 1922-1930.
8. Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003; 21: 1167-1173.
9. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003; 102: 2379-2386.
10. Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory leukemias. Blood. 2005; 105: 940-947.
11. Faderl S, Garcia-Manero G, Estrov Z, et al. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol. 2010; 28: 2755-2760.
12. Vardiman JW, Harris NL, Brunning RD,. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100: 2292-2302.
13. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108: 419-425.
14. Berry DA,. Monitoring accumulating data in a clinical trial. Biometrics. 1989; 45: 1197-1211.
15. Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010; 116: 3830-3834.
16. Bonate PL, Arthaud L, Cantrell WR Jr, et al. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev. 2006; 5: 855-863.
17. Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol. 2010; 28: 549-555.
18. Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol. 2010; 28: 2389-2395.
19. Sekeres MA, Roboz GJ, Odenike O, et al. Preliminary results of fixed-dose clofarabine (CLO) in patients who have failed hypomethylating agents for the treatment of myelodysplastic syndromes (MDS) [abstract]. Blood. 2010; 116: 1869.